Mohammed Qatanani
Chief Tech/Sci/R&D Officer bei SCHOLAR ROCK HOLDING CORPORATION
Vermögen: 3 Mio $ am 31.03.2024
Profil
Mohammed Qatanani is currently the Chief Scientific Officer at Scholar Rock Holding Corp.
He previously worked as the Director-Discovery Research at Alexion Pharmaceuticals, Inc. from 2015 to 2018 and as the Vice President-Program & Alliance Management at Dyne Therapeutics, Inc. from 2018 to 2021.
Dr. Qatanani completed his undergraduate and graduate degrees at the American University of Beirut and holds an MBA from Baylor College of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.02.2024 | 147 019 ( 0,19% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Mohammed Qatanani
| Unternehmen | Position | Beginn |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Chief Tech/Sci/R&D Officer | 01.09.2022 |
Ehemalige bekannte Positionen von Mohammed Qatanani
| Unternehmen | Position | Ende |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.09.2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2018 |
Ausbildung von Mohammed Qatanani
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
